Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Jun;85(6):615-22.
doi: 10.1038/clpt.2009.27. Epub 2009 Mar 18.

Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy

J S McCune  1 , A Batchelder, K A Guthrie, R Witherspoon, F R Appelbaum, B Phillips, P Vicini, D H Salinger, G B McDonald
Affiliations
Clinical Trial

Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy

J S McCune et al. Clin Pharmacol Ther. 2009 Jun.

Abstract

This study investigates the efficacy and safety of personalized cyclophosphamide (CY) dosing in 50 patients receiving CY along with total body irradiation (TBI). Participants received CY 45 mg/kg with subsequent therapeutic drug monitoring using Bayesian parameter estimation to personalize the second CY dose to a target area under the curve (AUC) for carboxyethylphosphoramide mustard (CEPM) (a reporter molecule for CY-derived toxins) and for hydroxycyclophosphamide (to ensure engraftment). The mean second CY dose was 66 mg/kg; the total dose ranged from 45 to 145 mg/kg. After completion of this phase II study, we compared participants' clinical outcomes with those of concurrent controls (n = 100) who received TBI along with standard CY doses of 120 mg/kg. Patients receiving personalized CY dosing had significantly lower postconditioning peak total serum bilirubin (P = 0.03); a 38% reduction in the hazard of acute kidney injury (AKI) (P = 0.03); and nonrelapse and overall survival rates similar to those in the controls (P = 0.70 and 0.63, respectively) despite the lower doses of CY administered to most of the patients in the personalized dosage group.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

None of the authors declared a conflict of interest.

Figures

Figure 1
Figure 1
Time to development of acute kidney injury by CY dosing method.
Figure 2
Figure 2
Non-relapse mortality (A), relapse (B), and overall survival (C) by CY dosing method.
Figure 3
Figure 3
Relapse of malignancy among patients receiving TBI 12 Gy plus standard CY dosing (120 mg/kg) vs. personalized CY dosing by type of hematologic malignancy (A and B) and by risk of relapse of malignancy after transplant (C and D).
Figure 4
Figure 4
Overall survival among patients receiving TBI 12 Gy plus standard CY dosing (120 mg/kg) vs. personalized CY dosing by type of hematologic malignancy (A and B) and by risk of relapse of malignancy after transplant (C and D).
See this image and copyright information in PMC

References

    1. Santos GW, et al. Marrow transplantation in man following cyclophosphamide. Transplant Proc. 1971;3:400–404. - PubMed
    1. Thomas ED, et al. Aplastic anaemia treated by marrow transplantation. Lancet. 1972;1:284–289. - PubMed
    1. Thomas ED, et al. Cure of leukemia by marrow transplantation. Leukemia Research. 1977;1:67–70.
    1. McDonald GB, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–267. - PubMed
    1. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease) Semin Liver Dis. 2002;22:27–42. - PubMed

Publication types

MeSH terms